WEST PHARMACEUTICAL SERVICES (WST) Stock Fundamental Analysis

NYSE:WST • US9553061055

249.02 USD
+1.14 (+0.46%)
At close: Feb 26, 2026
249.02 USD
0 (0%)
After Hours: 2/26/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall WST gets a fundamental rating of 6 out of 10. We evaluated WST against 58 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making WST a very profitable company, without any liquidiy or solvency issues. WST is valied quite expensively at the moment, while it does show a decent growth rate. This makes WST very considerable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year WST was profitable.
  • In the past year WST had a positive cash flow from operations.
  • In the past 5 years WST has always been profitable.
  • WST had a positive operating cash flow in each of the past 5 years.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 11.56%, WST belongs to the top of the industry, outperforming 91.38% of the companies in the same industry.
  • WST has a Return On Equity of 15.54%. This is amongst the best in the industry. WST outperforms 87.93% of its industry peers.
  • WST's Return On Invested Capital of 13.83% is amongst the best of the industry. WST outperforms 93.10% of its industry peers.
  • WST had an Average Return On Invested Capital over the past 3 years of 15.69%. This is above the industry average of 11.97%.
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROIC 13.83%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.69%
ROIC(5y)17.84%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • WST's Profit Margin of 16.06% is amongst the best of the industry. WST outperforms 86.21% of its industry peers.
  • WST's Profit Margin has been stable in the last couple of years.
  • WST has a better Operating Margin (20.16%) than 86.21% of its industry peers.
  • In the last couple of years the Operating Margin of WST has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 35.91%, WST is doing worse than 60.34% of the companies in the same industry.
  • WST's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.16%
PM (TTM) 16.06%
GM 35.91%
OM growth 3Y-8.65%
OM growth 5Y0.48%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), WST is creating some value.
  • The number of shares outstanding for WST has been reduced compared to 1 year ago.
  • WST has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, WST has an improved debt to assets ratio.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 12.79 indicates that WST is not in any danger for bankruptcy at the moment.
  • WST's Altman-Z score of 12.79 is amongst the best of the industry. WST outperforms 98.28% of its industry peers.
  • The Debt to FCF ratio of WST is 0.43, which is an excellent value as it means it would take WST, only 0.43 years of fcf income to pay off all of its debts.
  • WST has a better Debt to FCF ratio (0.43) than 91.38% of its industry peers.
  • WST has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • WST has a Debt to Equity ratio of 0.06. This is in the better half of the industry: WST outperforms 63.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.43
Altman-Z 12.79
ROIC/WACC1.28
WACC10.77%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that WST has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.02, WST is in line with its industry, outperforming 53.45% of the companies in the same industry.
  • A Quick Ratio of 2.34 indicates that WST has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.34, WST perfoms like the industry average, outperforming 51.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.34
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 8.00% over the past year.
  • WST shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.94% yearly.
  • WST shows a small growth in Revenue. In the last year, the Revenue has grown by 6.25%.
  • Measured over the past years, WST shows a small growth in Revenue. The Revenue has been growing by 7.44% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%

3.2 Future

  • Based on estimates for the next years, WST will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.76% on average per year.
  • WST is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.99% yearly.
EPS Next Y7.67%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
EPS Next 5Y10.76%
Revenue Next Year6.11%
Revenue Next 2Y6.14%
Revenue Next 3Y6.41%
Revenue Next 5Y5.99%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 34.16, WST can be considered very expensive at the moment.
  • WST's Price/Earnings ratio is in line with the industry average.
  • When comparing the Price/Earnings ratio of WST to the average of the S&P500 Index (27.21), we can say WST is valued slightly more expensively.
  • A Price/Forward Earnings ratio of 31.73 indicates a quite expensive valuation of WST.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of WST indicates a somewhat cheap valuation: WST is cheaper than 60.34% of the companies listed in the same industry.
  • WST is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 34.16
Fwd PE 31.73
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • WST's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. WST is cheaper than 63.79% of the companies in the same industry.
  • WST's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. WST is cheaper than 65.52% of the companies in the same industry.
Industry RankSector Rank
P/FCF 38.21
EV/EBITDA 21.8
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates WST does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of WST may justify a higher PE ratio.
PEG (NY)4.45
PEG (5Y)3.82
EPS Next 2Y10.28%
EPS Next 3Y10.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • WST has a yearly dividend return of 0.32%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.10, WST pays a better dividend. On top of this WST pays more dividend than 84.48% of the companies listed in the same industry.
  • With a Dividend Yield of 0.32, WST pays less dividend than the S&P500 average, which is at 1.80.
Industry RankSector Rank
Dividend Yield 0.32%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has been paying a dividend for at least 10 years, so it has a reliable track record.
  • WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.48%
Div Incr Years32
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 12.40% of the earnings are spent on dividend by WST. This is a low number and sustainable payout ratio.
  • The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP12.4%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

WEST PHARMACEUTICAL SERVICES

NYSE:WST (2/26/2026, 8:04:00 PM)

After market: 249.02 0 (0%)

249.02

+1.14 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-22
Inst Owners97.92%
Inst Owner Change-2.12%
Ins Owners0.33%
Ins Owner Change0.37%
Market Cap17.91B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target353.41 (41.92%)
Short Float %3.58%
Short Ratio2.69
Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years32
Div Non Decr Years34
Ex-Date01-28
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)-0.18%
PT rev (3m)-0.06%
EPS NQ rev (1m)1.83%
EPS NQ rev (3m)2.04%
EPS NY rev (1m)0%
EPS NY rev (3m)1.03%
Revenue NQ rev (1m)2.39%
Revenue NQ rev (3m)2.47%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 34.16
Fwd PE 31.73
P/S 5.83
P/FCF 38.21
P/OCF 23.73
P/B 5.64
P/tB 5.86
EV/EBITDA 21.8
EPS(TTM)7.29
EY2.93%
EPS(NY)7.85
Fwd EY3.15%
FCF(TTM)6.52
FCFY2.62%
OCF(TTM)10.49
OCFY4.21%
SpS42.73
BVpS44.15
TBVpS42.51
PEG (NY)4.45
PEG (5Y)3.82
Graham Number85.1
Profitability
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROCE 17.14%
ROIC 13.83%
ROICexc 17.71%
ROICexgc 18.48%
OM 20.16%
PM (TTM) 16.06%
GM 35.91%
FCFM 15.25%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.69%
ROIC(5y)17.84%
ROICexc(3y)20.15%
ROICexc(5y)23.86%
ROICexgc(3y)21.15%
ROICexgc(5y)25.26%
ROCE(3y)19.45%
ROCE(5y)22.11%
ROICexgc growth 3Y-14.58%
ROICexgc growth 5Y-3.63%
ROICexc growth 3Y-14.12%
ROICexc growth 5Y-2.75%
OM growth 3Y-8.65%
OM growth 5Y0.48%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.43
Debt/EBITDA 0.26
Cap/Depr 166.8%
Cap/Sales 9.3%
Interest Coverage 2065.67
Cash Conversion 95.41%
Profit Quality 94.98%
Current Ratio 3.02
Quick Ratio 2.34
Altman-Z 12.79
F-Score7
WACC10.77%
ROIC/WACC1.28
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y7.67%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
EPS Next 5Y10.76%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.11%
Revenue Next 2Y6.14%
Revenue Next 3Y6.41%
Revenue Next 5Y5.99%
EBIT growth 1Y5.95%
EBIT growth 3Y-6.72%
EBIT growth 5Y7.96%
EBIT Next Year40.02%
EBIT Next 3Y19.6%
EBIT Next 5Y14.44%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.


Can you provide the profitability details for WEST PHARMACEUTICAL SERVICES?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 7 / 10.


Can you provide the financial health for WST stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


How sustainable is the dividend of WEST PHARMACEUTICAL SERVICES (WST) stock?

The dividend rating of WEST PHARMACEUTICAL SERVICES (WST) is 6 / 10 and the dividend payout ratio is 12.4%.